• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Siemens PET/CT Receives FDA Clearance

Article

Siemens announced FDA has cleared features associated with their new Biograph mCT positron emission tomography/computed tomography scanner, which the company unveiled at RSNA in November 2011.

Siemens Healthcare announced FDA has cleared features associated with their new Biograph mCT positron emission tomography/computed tomography scanner, which the company unveiled at the RSNA meeting in November 2011.

The Biograph mCT provides precise measurement of metabolic processes and data qualification, as well as cardiac blood flow. The PET quantification allows physician to more precisely characterize cancer lesions, and the ability to measure myocardial blood flow allows for more accurate assessment of multi-vessel disease, the company said. In neurology, noninvasive assessment of the brain can potentially improve the diagnosis and management of patients who present with signs of dementia, according to the company.

The Biograph mCT incorporates Siemens’ OptisoHD (High Definition) detector system, which features a fine volumetric resolution of 87 mm. Also included is Time of Flight (TOF) and HD-PET, ensuring fast, precise images with minimum radiation dose, according to Siemens. The Quanti-QC daily system normalization can be performed overnight, calibrating and tuning the system to the right specifications.

The system also features a patient handling system to address differential deflection, the Auto Cardiac Registration that automatically aligns CT and PET heart images and reduces variability between users, as well as Siemens Molecular and Anatomical Registration Technologies, which the company said was a new form of attenuation correction for neurological images that doesn’t require CT data.

The Biograph mCT is expected to ship in May 2012.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.